ADMA Biologics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
ADMA is a late-stage biopharmaceutical company developing plasma-based biologics, including RI-002 for primary immune deficiency disease. Its Georgia plasma collection subsidiary generates current revenue and supplies plasma for manufacturing. The unaudited filing covers the three and six months ended June 30, 2014, compared with the same 2013 periods.
Financial Performance and Position
| Metric | Q2 2014 | Q2 2013 | Six Months 2014 | Six Months 2013 |
|---|---|---|---|---|
| Total revenue | $1.50 million | $0.74 million | $3.06 million | $1.54 million |
| Gross profit | $0.56 million | $0.26 million | $1.14 million | $0.52 million |
| Gross margin | 37.3% | 34.6% | 37.3% | 33.9% |
| Loss from operations | $(3.59) million | $(4.84) million | $(9.27) million | $(7.99) million |
| Net loss | $(3.96) million | $(4.90) million | $(9.87) million | $(8.14) million |
| Basic and diluted loss per share | $(0.43) | $(0.83) | $(1.06) | $(1.39) |
| Cash used in operating activities | — | $(9.34) million | $(5.70) million |
- Product revenue was $1.48 million in the quarter and $3.02 million year to date, substantially from plasma sales to one customer under the Biotest supply agreement. No revenue has yet been generated from the therapeutics research and development business.
- As of June 30, 2014, cash and cash equivalents were $17.87 million, short-term investments were $6.31 million, accounts receivable were $0.80 million, and working capital was approximately $22.7 million.
- Total liabilities were $15.58 million, including $9.71 million of notes payable, $1.54 million of deferred revenue, and a $0.25 million warrant liability. Stockholders’ equity was $12.30 million, down from $21.57 million at December 31, 2013.
- Net cash used in investing activities was $3.75 million, including $3.38 million invested in short-term investments and $0.37 million spent on property and equipment. Financing activities provided $4.81 million, primarily from Hercules debt proceeds.
Material Changes Versus the Prior Comparable Period
- Second-quarter revenue more than doubled, driven by increased plasma donor collections, promotional activity, and additional collection equipment. Six-month revenue increased 99%.
- Q2 research and development expense fell 49% to $1.78 million because substantially all clinical drug-product manufacturing costs had been completed in the first quarter. For the six-month period, R&D expense increased 24% to $6.11 million due to Phase III trial activity and manufacturing.
- Plasma center operating expense increased 52% in Q2 and 54% year to date as collection volumes, staffing, and facility supplies increased.
- General and administrative expense increased 41% in Q2 and 6% year to date, primarily due to commercial planning, market research, and related consulting costs.
- Q2 net loss improved by 19%, but the six-month net loss increased by 21% because higher year-to-date R&D costs and interest expense more than offset revenue growth.
- Interest expense increased substantially due to higher debt, debt discount amortization, deferred financing cost amortization, and payment-in-kind interest. The fair value of the Hercules warrant increased to $249,168 at June 30, 2014, producing a $29,580 year-to-date noncash expense.
Guidance, Outlook, Risks, and Unusual Items
- Management anticipated completing the RI-002 pivotal Phase III trial in the fourth quarter of 2014. The study enrolled 59 patients, more than 90% of planned infusions had been administered, and approximately half of the patients had completed scheduled infusions and visits. No serious adverse events related to RI-002 had been reported as of the filing date.
- Management expected preliminary Phase III data in the fourth quarter of 2014, a potential BLA filing in the first half of 2015, and potential first commercial sales as early as the first half of 2016, subject to successful trial results and FDA approval.
- Management expected R&D expense to remain generally stable through the remainder of 2014 while the Phase III study was completed, while G&A expense was expected to increase because of commercialization planning, market research, and additional staffing.
- Management believed available cash, short-term investments, projected revenue, and potentially available credit-facility funds could support operations into the first half of 2016. This estimate depends on assumptions regarding spending, revenue, trial execution, financing availability, and regulatory timing.
- The company has incurred losses and negative operating cash flow since inception and reported an accumulated deficit of $62.5 million. It has no existing commitment for future external funding and may require additional equity, debt, collaboration, or licensing financing. Additional financing may be unavailable or dilutive.
- The amended Hercules facility permits total borrowings of up to $15.0 million, subject to conditions. The loan carries interest, payment-in-kind interest, covenants, collateral rights, prepayment charges, and maturity no later than January 1, 2018. Principal repayment was scheduled to begin no later than April 1, 2015, subject to a possible extension.
- Georgia plasma-center leases require total minimum rent of approximately $3.3 million through the lease terms. Revenues are substantially dependent on one customer, and failure of RI-002 clinical, manufacturing, or regulatory efforts could materially affect liquidity and future operations.
- The company disclosed no material pending legal proceedings, no defaults upon senior securities, and effective disclosure controls as of June 30, 2014.
Important Facts for Investors to Verify
- Progress, safety results, endpoint achievement, and final data from the RI-002 Phase III trial.
- Timing and likelihood of the planned BLA filing, FDA approval, and potential 2016 commercialization.
- Actual cash burn versus management’s forecast that funding will last into the first half of 2016.
- Availability and conditions of the remaining Hercules financing tranche and the timing of debt repayment obligations.
- Concentration of revenue in the Biotest relationship and one primary customer.
- Future financing requirements, potential dilution, debt covenants, and the company’s ability to continue as a going concern.
- Whether plasma collection growth produces sustainable positive margins after collection-center operating costs.